Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

DOI record: { "DOI": "10.1016/j.eclinm.2021.101188", "ISSN": [ "2589-5370" ], "URL": "http://dx.doi.org/10.1016/j.eclinm.2021.101188", "alternative-id": [ "S2589537021004697" ], "article-number": "101188", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial" }, { "label": "Journal Title", "name": "journaltitle", "value": "eClinicalMedicine" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.eclinm.2021.101188" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2021 The Author(s). Published by Elsevier Ltd." } ], "author": [ { "affiliation": [], "family": "Labhardt", "given": "Niklaus D", "sequence": "first" }, { "affiliation": [], "family": "Smit", "given": "Mikaela", "sequence": "additional" }, { "affiliation": [], "family": "Petignat", "given": "Ianis", "sequence": "additional" }, { "affiliation": [], "family": "Perneger", "given": "Thomas", "sequence": "additional" }, { "affiliation": [], "family": "Marinosci", "given": "Annalisa", "sequence": "additional" }, { "affiliation": [], "family": "Ustero", "given": "Pilar", "sequence": "additional" }, { "affiliation": [], "family": "Diniz Ribeiro", "given": "Maria Pia", "sequence": "additional" }, { "affiliation": [], "family": "Ragozzino", "given": "Silvio", "sequence": "additional" }, { "affiliation": [], "family": "Nicoletti", "given": "Giovanni Jacopo", "sequence": "additional" }, { "affiliation": [], "family": "Faré", "given": "Pietro Benedetto", "sequence": "additional" }, { "affiliation": [], "family": "Andrey", "given": "Diego O", "sequence": "additional" }, { "affiliation": [], "family": "Jacquerioz", "given": "Frederique", "sequence": "additional" }, { "affiliation": [], "family": "Lebowitz", "given": "Dan", "sequence": "additional" }, { "affiliation": [], "family": "Agoritsas", "given": "Thomas", "sequence": "additional" }, { "affiliation": [], "family": "Meyer", "given": "Benjamin", "sequence": "additional" }, { "affiliation": [], "family": "Spechbach", "given": "Hervé", "sequence": "additional" }, { "affiliation": [], "family": "Salamun", "given": "Julien", "sequence": "additional" }, { "affiliation": [], "family": "Guessous", "given": "Idris", "sequence": "additional" }, { "affiliation": [], "family": "Chappuis", "given": "François", "sequence": "additional" }, { "affiliation": [], "family": "Kaiser", "given": "Laurent", "sequence": "additional" }, { "affiliation": [], "family": "Decosterd", "given": "Laurent Arthur", "sequence": "additional" }, { "affiliation": [], "family": "Grinsztejn", "given": "Beatriz", "sequence": "additional" }, { "affiliation": [], "family": "Bernasconi", "given": "Enos", "sequence": "additional" }, { "affiliation": [], "family": "Cardoso", "given": "Sandra Wagner", "sequence": "additional" }, { "affiliation": [], "family": "Calmy", "given": "Alexandra", "sequence": "additional" }, { "affiliation": [], "family": "Team", "given": "for the COPEP Study", "sequence": "additional" } ], "container-title": "eClinicalMedicine", "container-title-short": "eClinicalMedicine", "content-domain": { "crossmark-restriction": true, "domain": [ "thelancet.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2021, 11, 6 ] ], "date-time": "2021-11-06T03:47:34Z", "timestamp": 1636170454000 }, "deposited": { "date-parts": [ [ 2023, 3, 21 ] ], "date-time": "2023-03-21T14:18:33Z", "timestamp": 1679408313000 }, "indexed": { "date-parts": [ [ 2024, 8, 16 ] ], "date-time": "2024-08-16T00:51:04Z", "timestamp": 1723769464803 }, "is-referenced-by-count": 4, "issued": { "date-parts": [ [ 2021, 12 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 12, 1 ] ], "date-time": "2021-12-01T00:00:00Z", "timestamp": 1638316800000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 10, 21 ] ], "date-time": "2021-10-21T00:00:00Z", "timestamp": 1634774400000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S2589537021004697?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S2589537021004697?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "101188", "prefix": "10.1016", "published": { "date-parts": [ [ 2021, 12 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Elsevier BV", "reference": [ { "key": "10.1016/j.eclinm.2021.101188_bib0001", "unstructured": "A year without precedent: WHO's COVID-19 response. https://www.who.int/news-room/spotlight/a-year-without-precedent-who-s-covid-19-response (accessed March 16, 2021)." }, { "DOI": "10.1016/S1473-3099(20)30471-0", "article-title": "Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study", "author": "Jing", "doi-asserted-by": "crossref", "first-page": "1141", "journal-title": "The Lancet Infectious Diseases", "key": "10.1016/j.eclinm.2021.101188_bib0002", "volume": "20", "year": "2020" }, { "DOI": "10.1001/jamanetworkopen.2020.31756", "article-title": "Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis", "author": "Madewell", "doi-asserted-by": "crossref", "journal-title": "JAMA Netw Open", "key": "10.1016/j.eclinm.2021.101188_bib0003", "volume": "3", "year": "2020" }, { "DOI": "10.1016/S2468-2667(21)00012-8", "doi-asserted-by": "crossref", "key": "10.1016/j.eclinm.2021.101188_bib0004", "unstructured": "Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. The Lancet Public Health 2021; 0. DOI:10.1016/S2468-2667(21)00012-8." }, { "DOI": "10.1016/S0140-6736(20)31558-0", "article-title": "Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study", "author": "de", "doi-asserted-by": "crossref", "first-page": "898", "journal-title": "The Lancet", "key": "10.1016/j.eclinm.2021.101188_bib0005", "volume": "396", "year": "2020" }, { "article-title": "Reinfection with SARS-CoV-2: Implications for Vaccines", "author": "Cohen", "journal-title": "Clin Infect Dis", "key": "10.1016/j.eclinm.2021.101188_bib0006", "year": "2020" }, { "DOI": "10.1038/d41586-021-00121-z", "article-title": "Fast-spreading COVID variant can elude immune responses", "author": "Callaway", "doi-asserted-by": "crossref", "first-page": "500", "journal-title": "Nature", "key": "10.1016/j.eclinm.2021.101188_bib0007", "volume": "589", "year": "2021" }, { "article-title": "New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications", "author": "Abdool Karim", "issue": "null", "journal-title": "New England Journal of Medicine", "key": "10.1016/j.eclinm.2021.101188_bib0008", "volume": "0", "year": "2021" }, { "DOI": "10.1136/bmj.n1077", "article-title": "Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn", "author": "Mahase", "doi-asserted-by": "crossref", "first-page": "n1077", "journal-title": "BMJ", "key": "10.1016/j.eclinm.2021.101188_bib0009", "volume": "373", "year": "2021" }, { "article-title": "Regeneron Pharmaceuticals", "key": "10.1016/j.eclinm.2021.101188_bib0010", "year": "2021" }, { "key": "10.1016/j.eclinm.2021.101188_bib0011", "unstructured": "Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COVTM (casirivimab with imdevimab) | Regeneron Pharmaceuticals Inc. https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars/ (accessed April 19, 2021)." }, { "author": "Lilly", "journal-title": "clinicaltrials.gov", "key": "10.1016/j.eclinm.2021.101188_bib0012", "year": "2021" }, { "DOI": "10.1056/NEJMoa2016638", "article-title": "A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19", "author": "Boulware", "doi-asserted-by": "crossref", "first-page": "517", "journal-title": "N Engl J Med", "key": "10.1016/j.eclinm.2021.101188_bib0013", "volume": "383", "year": "2020" }, { "article-title": "Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo", "journal-title": "clinicaltrials.gov", "key": "10.1016/j.eclinm.2021.101188_bib0014", "year": "2020" }, { "key": "10.1016/j.eclinm.2021.101188_bib0015", "unstructured": "Control of COVID-19 Outbreaks in Long Term Care - Tabular View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT04448119 (accessed March 22, 2021)." }, { "DOI": "10.1016/j.ijantimicag.2020.106248", "article-title": "Lower incidence associated with prophylactic administration of ivermectin", "author": "Hellwig", "doi-asserted-by": "crossref", "journal-title": "International Journal of Antimicrobial Agents", "key": "10.1016/j.eclinm.2021.101188_bib0016", "volume": "57", "year": "2021" }, { "DOI": "10.1136/bmj.m2980", "article-title": "Drug treatments for covid-19: living systematic review and network meta-analysis", "author": "Siemieniuk", "doi-asserted-by": "crossref", "first-page": "m2980", "journal-title": "BMJ", "key": "10.1016/j.eclinm.2021.101188_bib0017", "volume": "370", "year": "2020" }, { "DOI": "10.1016/j.cmi.2021.01.013", "article-title": "Prophylaxis for COVID-19: a systematic review", "author": "Smit", "doi-asserted-by": "crossref", "journal-title": "Clin Microbiol Infect", "key": "10.1016/j.eclinm.2021.101188_bib0018", "year": "2021" }, { "DOI": "10.1136/bmj.n949", "article-title": "Prophylaxis against covid-19: living systematic review and network meta-analysis", "author": "Bartoszko", "doi-asserted-by": "crossref", "first-page": "n949", "journal-title": "BMJ", "key": "10.1016/j.eclinm.2021.101188_bib0019", "volume": "373", "year": "2021" }, { "DOI": "10.1016/j.antiviral.2020.104786", "article-title": "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro", "author": "Choy", "doi-asserted-by": "crossref", "journal-title": "Antiviral Res", "key": "10.1016/j.eclinm.2021.101188_bib0020", "volume": "178", "year": "2020" }, { "DOI": "10.1056/NEJMoa2015294", "article-title": "Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome", "author": "Arabi", "doi-asserted-by": "crossref", "first-page": "1645", "journal-title": "New England Journal of Medicine", "key": "10.1016/j.eclinm.2021.101188_bib0021", "volume": "383", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)32013-4", "article-title": "Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial", "author": "Horby", "doi-asserted-by": "crossref", "first-page": "1345", "journal-title": "The Lancet", "key": "10.1016/j.eclinm.2021.101188_bib0022", "volume": "396", "year": "2020" }, { "DOI": "10.1056/NEJMoa2023184", "article-title": "Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results", "author": "Solidarity Trial Consortium", "doi-asserted-by": "crossref", "first-page": "497", "journal-title": "N Engl J Med", "key": "10.1016/j.eclinm.2021.101188_bib0023", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2001282", "article-title": "A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19", "author": "Cao", "doi-asserted-by": "crossref", "first-page": "1787", "journal-title": "New England Journal of Medicine", "key": "10.1016/j.eclinm.2021.101188_bib0024", "volume": "382", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31042-4", "article-title": "Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial", "author": "Hung", "doi-asserted-by": "crossref", "first-page": "1695", "journal-title": "The Lancet", "key": "10.1016/j.eclinm.2021.101188_bib0025", "volume": "395", "year": "2020" }, { "article-title": "RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis", "author": "Mehra", "journal-title": "The Lancet", "key": "10.1016/j.eclinm.2021.101188_bib0026", "volume": "0", "year": "2020" }, { "key": "10.1016/j.eclinm.2021.101188_bib0027", "unstructured": "BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING. CROI Conference. https://www.croiconference.org/abstract/bamlanivimab-prevents-covid-19-morbidity-and-mortality-in-nursing-home-setting/ (accessed May 4, 2021)." }, { "key": "10.1016/j.eclinm.2021.101188_bib0028", "unstructured": "CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS. CROI Conference. https://www.croiconference.org/abstract/casirivimab-with-imdevimab-antibody-cocktail-for-covid-19-prevention-interim-results/ (accessed May 6, 2021)." }, { "key": "10.1016/j.eclinm.2021.101188_bib0029", "unstructured": "REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR. https://www.croiconference.org/abstract/reduction-in-infectious-sars-cov-2-in-treatment-study-of-covid-19-with-molnupiravir/ (accessed May 6, 2021)." }, { "DOI": "10.1002/cpt.2014", "article-title": "Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2", "author": "Thakur", "doi-asserted-by": "crossref", "first-page": "1176", "journal-title": "Clin Pharmacol Ther", "key": "10.1016/j.eclinm.2021.101188_bib0030", "volume": "108", "year": "2020" }, { "DOI": "10.1186/s13063-021-05134-7", "article-title": "Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial", "author": "Tan", "doi-asserted-by": "crossref", "first-page": "224", "journal-title": "Trials", "key": "10.1016/j.eclinm.2021.101188_bib0031", "volume": "22", "year": "2021" }, { "key": "10.1016/j.eclinm.2021.101188_bib0032", "unstructured": "Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort | PNAS. https://www.pnas.org/content/118/8/e2017962118 (accessed May 6, 2021)." } ], "reference-count": 32, "references-count": 32, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S2589537021004697" } }, "score": 1, "short-title": [], "source": "Crossref", "special_numbering": "C", "subject": [], "subtitle": [], "title": "Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "42" }